Amylyx Pharmaceuticals, Inc. (AMLX)
B
Pipeline Grade
Financial Position (from SEC Filings)
$230.1M
Cash & Equivalents
$36.9M
Quarterly Burn Rate
19 mo
Est. Cash Runway
$1,564M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (1 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
SODIUM PHENYLBUTYRATE, TAURURSODIOL
RELYVRIO |
NDA | ALS, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Atypical Parkinsonism, Central Nervous System Diseases, Motor Neuron Disease, Nervous System Diseases, Neurodegenerative Diseases, Neuromuscular Diseases, Post Bariatric Hypoglycemia, Progressive Supranuclear Palsy, PSP, Spinal Cord Diseases, TDP-43 Proteinopathies, Wolfram Syndrome |
Upcoming Catalysts
No upcoming catalysts detected for this company.